CompletedPhase 2NCT00003305
Aminopterin in Treating Patients With Refractory Leukemia
Studying Acute lymphoblastic leukemia
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Genzyme, a Sanofi Company
- Principal Investigator
- Barton A. Kamen, MD, PhDRutgers Cancer Institute of New Jersey
- Intervention
- aminopterin(drug)
- Enrollment
- 75 enrolled
- Eligibility
- All sexes
- Timeline
- 1997 – 2007
Study locations (14)
- Advanced Urology Medical Center, Anaheim, California, United States
- South Coast Urological Medical Group, Laguana Hills, California, United States
- Urology Specialists, P.C., Waterbury, Connecticut, United States
- Barzell, Whitmore, Treiman and Dunne - The Urology Treatment Center, Sarasota, Florida, United States
- University of Chicago Cancer Research Center, Chicago, Illinois, United States
- 206 Research Associates, Greenbelt, Maryland, United States
- Mid Atlantic Clinical Research, Rockville, Maryland, United States
- Cancer Institute of New Jersey, New Brunswick, New Jersey, United States
- Medical & Clinical Research Associates, LLC, Bay Shore, New York, United States
- Herbert Irving Comprehensive Cancer Center, New York, New York, United States
- Medical City Dallas Hospital, Dallas, Texas, United States
- Urology Centers of North Texas, Dallas, Texas, United States
- Urology San Antonio Research, San Antonio, Texas, United States
- Children's Hospital and Regional Medical Center - Seattle, Seattle, Washington, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT00003305 on ClinicalTrials.govOther trials for Acute lymphoblastic leukemia
Additional recruiting or active studies for the same condition.
- RECRUITINGNANCT05621291A Study to Evaluate Next-Generation Sequencing (NGS) Testing and Monitoring of B-cell Recovery to Guide Management Following Chimeric Antigen Receptor T-cell (CART) Induced Remission in Children and Young Adults With B Lineage Acute Lymphoblastic Leu...National Cancer Institute (NCI)
- RECRUITINGPHASE2NCT07328503CD22 CAR T-cells to Extend Remission Following Commercial CD19 CAR T-cells in Children, Adolescents, and Adults With Relapsed/Refractory B-cell Acute Lymphoblastic LeukemiaNational Cancer Institute (NCI)
- RECRUITINGPHASE2NCT06738368Etoposide, Prednisone, Vincristine, Cyclophosphamide, and Doxorubicin (DA-EPOCH) With or Without Rituximab Plus Recombinant Erwinia Asparaginase (JZP458) for the Treatment of Newly Diagnosed Ph Negative B-Acute Lymphoblastic Leukemia or T Acute Lymphoblastic LeukemiaUniversity of Washington
- ENROLLING BY INVITATIONNCT07511959Autologous Exosomes From Platelet-rich Plasma as a Modern Tool of Regenerative DentistryWroclaw Medical University
- RECRUITINGNANCT07191119Transcutaneous Auricular Vagus Nerve Stimulation for Insomnia in Survivors of Childhood Acute Lymphoblastic LeukemiaSt. Jude Children's Research Hospital
- RECRUITINGNANCT07177183Low Serum Creatinine as a Predictor of Prolonged Mechanical Ventilation and Weaning FailureUniversity Hospital Ostrava
- RECRUITINGPHASE2NCT07275762Y-4 to Treat the Postherpetic NeuralgiaNeurodawn Pharmaceutical Co., Ltd.
- ENROLLING BY INVITATIONNCT07515430The Association Between Gut Microbiome Composition Signature and Cancer-related Symptoms in Children With Acute Lymphoblastic LeukemiaSun Yat-sen University